Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase II/III, Non-inferiority Trial
Phase of Trial: Phase II/III
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- Acronyms RISAPS
- 31 Jul 2019 Planned End Date changed from 1 Oct 2022 to 15 Dec 2022.
- 31 Jul 2019 Planned initiation date changed from 1 Jan 2019 to 15 Sep 2019.
- 26 Jul 2019 Status changed from not yet recruiting to recruiting.